

Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Approval: CTP JV Pty Ltd

I, Christopher Paul Burgess, Chief Health Officer:

- (a) under section 254(1) of the *Medicines, Poisons and Therapeutic Goods Act 2012* (***the Act***), approve each Scheduled substance treatment protocol specified in Schedule A, and
- (b) under section 254(3) of the Act, state that each Schedule Substance Treatment Protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this Notice.

Dated 28 August 2026

Chief Health Officer

Schedule A

Title	Publication Date	Author
Central Tanami Project – Joint Venture (CTP JV)	28 August 2026	Medicines and Poisons Northern Territory Government, NT Health

CTP JV Pty Ltd - SSTP

Areas Applicable	NT Wide	
Health Professionals authorised by this SSTP	Nurses and Paramedics employed by or contracted to Central Tanami Projects Joint Venture – CTP JV Pty Ltd (ABN 86 648 942 652)	
Scheduled Substance(s)	Schedule 3 and 4 Medicines Adenosine Hyoscine butyl-bromide Adrenaline (epinephrine) Ibuprofen Amethocaine Indomethacin Amiodarone Ipratropium Amoxycillin Ketorolac Atropine Levonorgestrel Azithromycin Lidocaine Benztropine Mefenamic Acid Betamethasone Methoxyflurane Ceftriaxone Metoclopramide Cephalexin Metronidazole Cephazolin Metoprolol Chloramphenicol Midazolam Clavulanic Acid Mupirocin Clotrimazole Naloxone Ciprofloxacin Neomycin Codeine – when compounded with paracetamol in divided preparations containing codeine Ondansetron Colchicine Penicillin	

	Dexamethasone Diclofenac Dicloxacillin Diazepam Enoxaparin Erythromycin Esomeprazole Fluconazole Flucloxacillin Fluorescein Fluticasone Framycetin Furosemide Glucagon Glyceryl Trinitrate Gramicidin Hydrocortisone Schedule 8 Medicines Fentanyl Ketamine	Prednisolone Promethazine Prochlorperazine Pseudoephedrine Roxithromycin Salbutamol Temazepam Tenecteplase Terbinafine Tramadol Trimethoprim Triamcinolone Vaccine - Diphtheria Vaccine – Influenza Vaccine – Pertussis Valaciclovir Morphine
Indication, Dose, Route, Frequency	- Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in Complete Corporate Health Medication Administration Guidelines as in force from time to time. - Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner.	

Contraindications and/or Exclusions*	- Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol. - Any contraindications or exclusions as outlined in the individual scheduled substance product information. - Any contraindication or exclusions as outlined in Complete Corporate Health Medication Administration Guidelines		
Health Professional Accreditation Requirements	<u>Nurses must:</u> - Hold registration with the Nursing & Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients - Maintain continuing professional development related to skills and competencies required for delivery of medicines <u>Paramedics must:</u> - Hold registration with the Paramedicine Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients - Maintain continuing professional development related to skills and competencies required for delivery of medicines		
Chief Health Officer	Signature	Name	Date
	09-D26-50679	Paul Burgess	28/08/2026
Period of effect	This SSTP is in effect until 28/08/2028 unless revoked earlier		
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer’s product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			